http://orcid.org/0000-0003-2095-4971
References
- Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2002;2(12):910–917. doi:10.1038/nrc950.
- Scheicher R, Hoelbl-Kovacic A, Bellutti F, Tigan A-S, Prchal-Murphy M, Heller G, Schneckenleithner C, Salazar-Roa M, Ochbauer-Uller S, Zuber J, et al. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood. 2015; 125(1): 90–101. doi:10.1182/blood-2014-06.
- Uras IZ, Walter GJ, Scheicher R, Bellutti F, Prchal-Murphy M, Tigan AS, Valent P, Heidel FH, Kubicek S, Scholl C, et al. Palbociclib treatment of FLT3-ITD+ 1 AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. Blood. 2016; 127(23): 2890–2902. doi:10.1182/blood-2015-11.
- Kollmann K, Heller G, Schneckenleithner C, Warsch W, Scheicher R, Ott RG, Schäfer M, Fajmann S, Schlederer M, Schiefer AI, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013; 24(2): 167–181. doi:10.1016/j.ccr.2013.07.012.
- Kollmann K, Sexl V. CDK6 and p16 INK4A in lymphoid malignancies. Oncotarget. 2013;4(11):1858–1859. doi:10.18632/oncotarget.1541.
- Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280–292. doi:10.1038/nrm.2016.27.
- Bellutti F, Tigan A-S, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, et al. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discov. 2018; 8(7): 884–897. doi:10.1158/2159-8290.CD-17-0912.
- Li Y, Chitnis N, Nakagawa H, Kita Y, Natsugoe S, Yang Y, Li Z, Wasik M, Klein-Szanto AJP, Rustgi AK, et al. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers. Cancer Discov. 2015; 5(3): 288–303. doi:10.1158/2159-8290.CD-14-0625.
- Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S, Bradner JE. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science. 2015;348(6241):1376–1381. doi:10.1126/science.aab1433.
- Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, Zhang T, Kwiatkowski N, Boukhali M, Green JL, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018; 14(2): 163–170. doi:10.1038/nchembio.2538.